Strata Critical Medical, Inc.
NASDAQ:SRTAAirlines, Airports & Air Services
-$0.03 today
- Market cap
- $443.03M
- Beta
- 2.20
- P/E (TTM)
- 9.7
- EPS (TTM)
- $0.60
Volume 0.99M
Average 0.91M
SRTA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Strata Critical Medical, Inc.NASDAQ: SRTA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $3.06M rose 80.3% year over year, ahead of the +57.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.7% from the prior quarter. Over 3 fiscal years it compounded at +6.4% a year.
Context
- Depreciation & amortization amounted to 3.5% of revenue in FY2025, up 1.1 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +80.3% holds above the trailing-twelve-month pace of +57.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 6.9M USD
- Year-over-year change
- +15.7%
- 4-year CAGR
- +84.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.9M | +15.7% |
| FY2024 | 2024-12-31 | 5.96M | -16.2% |
| FY2023 | 2023-12-31 | 7.11M | +24.2% |
| FY2022 | 2022-12-31 | 5.73M | +860.6% |
| FY2021 | 2021-09-30 | 596K | — |
Depreciation & Amortization vs competitors
How SRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +57.4% is the highest of 10, against a peer median of -3.0%.
- Depreciation & amortization amounts to 3.8% of revenue for SRTA, versus a peer median of 4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $146.4M USD | +5.3% | +24.0% | 9.5% | |
| LTM Mar 2026 | $26.47M USD | -14.4% | +11.0% | 14.5% | |
| LTM Mar 2026 | $26.06M USD | +17.6% | +8.3% | 3.0% | |
| LTM Mar 2026 | $22M USD | -15.6% | +0.7% | 5.7% | |
| LTM Feb 2026 | $17.13M USD | +3.4% | -0.4% | 4.4% | |
| LTM Mar 2026 | $12.5M USD | -3.0% | +7.8% | 14.2% | |
| LTM Mar 2026 | $12.36M USD | +1.7% | +5.3% | 2.8% | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | $9.55M USD | +57.4% | +6.4% | 3.8% |
| LTM Mar 2026 | $9.18M USD | -10.2% | -13.1% | 1.1% | |
| LTM Mar 2026 | $5.39M USD | -11.0% | -18.1% | 0.4% | |
| LTM Mar 2026 | £2.88M GBP | — | -3.6% | — | |
| Peer median (excluding SRTA) | — | -3.0% | +3.0% | 4.4% | |
Competitors are the stored peer set for SRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 50.53M | 146.12M | 225.18M | 248.69M | 197.14M |
| Cost of Revenue | 40.01M | 123.85M | 183.06M | 189.77M | 158.82M |
| Gross Profit | 10.52M | 22.28M | 42.12M | 58.92M | 38.33M |
| Gross Margin | 20.8% | 15.2% | 18.7% | 23.7% | 19.4% |
| Research & Development | 1.68M | 5.55M | 4.63M | 3.18M | 3.05M |
| Selling, General & Admin | 32.93M | 70.26M | 105.61M | 89.66M | 45.08M |
| Operating Expenses | 34.61M | 75.8M | 110.24M | 92.85M | 48.13M |
| Depreciation & Amortization | 596K | 5.73M | 7.11M | 5.96M | 6.9M |
| EBITDA | (43.1M) | (22.31M) | (50.43M) | (21.6M) | (13.17M) |
| EBITDA Margin | -85.3% | -15.3% | -22.4% | -8.7% | -6.7% |
| Operating Income | (24.09M) | (53.53M) | (68.12M) | (33.93M) | (9.81M) |
| Operating Margin | -47.7% | -36.6% | -30.3% | -13.6% | -5.0% |
| Interest Income | 460K | 3.43M | 8.44M | 7.21M | 4.24M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (19.6M) | 25.5M | 10.58M | 6.36M | (10.26M) |
| Income Before Tax | (43.7M) | (28.03M) | (57.54M) | (27.56M) | (20.07M) |
| Pre-Tax Margin | -86.5% | -19.2% | -25.6% | -11.1% | -10.2% |
| Income Tax Expense | (3.64M) | (772K) | (1.47M) | (255K) | 0 |
| Net Income | (40.05M) | (27.26M) | (56.08M) | (27.31M) | (15.65M) |
| Net Margin | -79.3% | -18.7% | -24.9% | -11.0% | -7.9% |
| EPS (Basic) | (0.57) | (0.38) | (0.76) | (0.35) | (0.19) |
| EPS (Diluted) | (0.57) | (0.38) | (0.76) | (0.35) | (0.19) |
| Weighted Avg Shares | 70.1M | 71.24M | 73.52M | 77.5M | 82.45M |
| Weighted Avg Shares (Diluted) | 70.1M | 71.24M | 73.52M | 77.5M | 82.45M |
Strata Critical Medical, Inc.
NASDAQ:SRTA
Intrinsic Alpha fair value
Locked
Current Price
$4.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.